Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)

被引:107
作者
Lee, SS
Heathcote, EJ
Reddy, KR
Zeuzem, S
Fried, MW
Wright, TL
Pockros, PJ
Häussinger, D
Smith, CI
Lin, A
Pappas, SC
机构
[1] Univ Calgary, Fac Med, Calgary, AB T2N 4N1, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Miami, Sch Med, Miami, FL USA
[4] Univ Hosp Frankfurt, Frankfurt, Germany
[5] Univ N Carolina, Chapel Hill, NC USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Scripps Res Inst, La Jolla, CA 92037 USA
[8] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[9] Minnesota Clin Res Ctr, St Paul, MI USA
[10] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
关键词
hepatitis C; pegylated interferon; peginterferon alfa-2a (40KD); interferon alfa-2a; prognostic factors; predictability; viral kinetics; hepatitis C virus RNA;
D O I
10.1016/S0168-8278(02)00211-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Baseline factors and early decline in serum hepatitis C virus RNA are predictive of sustained virological response to interferon therapy in patients with chronic hepatitis C. We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD). Methods: Data were pooled from three randomized trials involving 814 patients treated with peginterferon alfa-2a (40KD) (90, 135, or 180 mug). Stepwise and multiple logistic regression identified independent baseline factors associated with response. Receiver operating characteristic curves for both absolute values and log(10) decline in viral RNA at 4, 8, 12 and 24 weeks of therapy were created. Results: Independent prognostic factors for sustained virological response included viral genotype non-1, low pretreatment viral load, age (<40 years), no cirrhosis and body weight (<85 kg). In addition, alanine aminotransferase quotient (>3) and histological activity index score (>10) were also independently prognostic. Receiver operating characteristic curves showed that detectable or less than 2-log(10) decline in viral RNA at week 12 predicted sustained virological non-response (negative predictive value is 98%). Conclusions: In patients with chronic hepatitis C treated with peginterferon alfa-2a (40KD), the decision to continue or stop treatment can be made as early as week 12. (C) 2002 European Association for the Study of the Liver. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:500 / 506
页数:7
相关论文
共 28 条
[11]   Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay [J].
Konnick, EQ ;
Erali, M ;
Ashwood, ER ;
Hillyard, DR .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (03) :768-773
[12]   Statistical models for predicting a beneficial response to interferon-α in patients with chronic hepatitis B [J].
Lau, DTY ;
Comanor, L ;
Minor, JM ;
Everhart, JE ;
Wuestehube, LJ ;
Hoffnagle, JH .
JOURNAL OF VIRAL HEPATITIS, 1998, 5 (02) :105-114
[13]   Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: Calibration to international units, enhanced genotype reactivity, and performance characteristics [J].
Lee, SC ;
Antony, A ;
Lee, N ;
Leibow, J ;
Yang, JQ ;
Soviero, S ;
Gutekunst, K ;
Rosenstraus, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (11) :4171-4179
[14]   Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B [J].
Lok, ASF ;
Ghany, MG ;
Watson, G ;
Ayola, B .
JOURNAL OF VIRAL HEPATITIS, 1998, 5 (03) :171-178
[15]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[16]  
MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1002/hep.1840220406
[17]   Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C [J].
McHutchison, JG ;
Gordon, SC ;
Schiff, ER ;
Shiffman, ML ;
Lee, WM ;
Rustgi, VK ;
Goodman, ZD ;
Ling, MH ;
Cort, S ;
Albrecht, JK .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1485-1492
[18]   Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy [J].
McHutchison, JG ;
Shad, JA ;
Gordon, SC ;
Morgan, TR ;
Ling, MH ;
Garaud, JJ ;
Albrecht, JK ;
Dienstag, JL .
JOURNAL OF VIRAL HEPATITIS, 2001, 8 (06) :414-420
[19]  
ORITO E, 1994, J MED VIROL, V44, P410, DOI 10.1002/jmv.1890440418
[20]  
POCKROS PJ, 2001, EVALUATION 2 DOSES P